Navigation Links
The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting

HACKENSACK, N.J. (November 22, 2010) The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American Society of Hematology (ASH) Meeting in Orlando from December 4 6. The presentations showcased at ASH will include 12 oral sessions and 28 poster presentations, including multicenter, international trials in collaboration with leading cancer institutions, such as the National Cancer Institute, MD Anderson, Dana-Farber, Mayo Clinic, Cleveland Clinic and Memorial Sloan Kettering.

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. The research presented by the John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and bone marrow stem cell transplantation, sickle cell, leukemia, and myelodysplastic syndromes.

"We have a long-standing commitment to expand our research capabilities, which includes investing in clinical and research talent, new technology, and infrastructure improvements. As a result, we are presenting twice as many studies compared to last year at this premier hematology conference," said Andre Goy, M.D., M.S., deputy director, director of clinical and translational research, and chief of lymphoma of the John Theurer Cancer Center. "Furthermore, six investigators were first authors of 13 studies, including multicenter trials, establishing our leadership role in the fight against cancer."

In January 2011, the John Theurer Cancer Center will begin treating patients in a new building that will allow the cancer center to further expand its commitment to research and innovation. Breakthrough advances being pioneered in this new facility will include a dedicated Phase 1 Unit, tumor banking to help development of biomarkers as part of next generation clinical trials, new state-of-the-art radiotherapy systems, and functional imaging.

Lead authors presenting at ASH from the John Theurer Cancer Center include Dr. Goy; David Siegel, M.D. , co-chief, multiple myeloma; David Vesole, M.D., co-chief and research director, multiple myeloma; Stuart Goldberg, M.D., chief, leukemia; Anthony R. Mato, M.D., attending, lymphoma; and Jenny Zilberberg, Ph.D., associate, research.

"We are thankful to the hundreds of patients who participated in these clinical trials, which allows us to study some of the most promising cancer-treatment candidates in the pipeline," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer and professor and vice president of cancer services, the John Theurer Cancer Center. "Their contribution is essential as our researchers and clinicians endeavor to advance treatment and develop new therapies in this fight against cancer."

John Theurer Cancer Center 2010 ASH Abstract Highlights

The following are key abstracts being presented at ASH from the John Theurer Cancer Center. For a complete list of the 40 abstracts and ongoing updates, please visit

Blood and Marrow Stem Cell Transplantation

  • 38: Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial Siegel D., Vesole D., et al. Oral Session: December 6, 2010 Time: 11:45am
  • 366: Health-Related Quality-of-Life Among Adult Matched Unrelated Stem Cell Donors: A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Randomized Trial of Marrow Versus PBSC Donation Switzer G., Rowley S., et al. Oral Session: December 6, 2010 Time: 11:45am
  • 4288: Successful Implementation of GM-CSF Cellular Immunotherapy for the Treatment of Multiple Myeloma In a Mouse Model of Autologous Bone Marrow Transplantation Ziberberg J., Stein J., Friedman T., and Korngold R. Poster Session: December 6, 2010 Time: 6:00pm 8:00pm
  • 521: Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy Fowler D., Rowley S., Donato M., Goy A., Friedman T., Korngold R., Pecora A., et al. Oral Session: December 6, 2010 Time: 3:45 pm (in collaboration as sole institution with the National Cancer Institute)

Multiple Myeloma

  • 308: Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD) Vesole D., Siegel D., et al. Oral Session: December 6, 2010 Time: 7:15am
  • 985: Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM) Siegel D., et al. Oral Session: December 7, 2010 Time: 7:30am
  • 1952: Vorinostat Combined with Bortezomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program Siegel D., et al. Poster Session December 4, 2010 Time: 5:30pm 7:30pm
  • 3017: Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma: A URCC/ECOG Phase III Study Vesole D., et al. Poster Session: December 5, 2010 Time: 6:00pm 8:00pm
  • 3065: Vorinostat Overcomes Lenalidomide Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance in Relapsed/Refractory Multiple Myeloma Siegel D., McBride L., Bilotti E., Schmidt L., McNeill A., Donadio K., Olivo K., Bendarz U., Vesole D., et al. Poster Session: December 5, 2010 Time: 6:00pm 8:00pm


  • 426: A Novel 3D Co-Culture System for Isolation and Amplification of Primary Liquid Cancer Cells Caicedo-Carvahal C., Goy A., Pecora A., Mato A., Feldman T., Suh S. Oral Session: December 6, 2010 Time: 11:45am
  • 430: Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial Goy A., Feldman T., et al. Oral Session: December 6, 2010 Time: 11:15am
  • 1753: Pralatrexate is Effective in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens Goy A., et al. Poster Session: December 4, 2010 Time: 5:30pm 7:30pm
  • 1782: R-HCVAD/R-MTX-Arac (R-HCVAD) Overcomes Risk Features Associated with Inferior Outcomes in the Treatment of Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Mato A., Feldman T., Zielonka T., Bhattacharyya P., Campaiola A., Shah R., Rosario M., Bejot C., Stives S., Curtin M., Vicioso R., Goldberg S., Pecora A., and Goy A. Poster Session: December 4, 2010 Time: 5:30pm 7:30 pm
  • 3131: Post-Treatment (not interim) PET-CT Scan Status is Highly Predictive of Outcome in Mantle Cell Lymphoma Treated with R-Hypercvad or ASCT Mato, A., Zielonka T., Feldman T.,Agress H., Panush D., Miller M., Toth P., Lizott Jr. P., Rowley S., Donato M., Goldberg S., Pecora A., Goy A., et al. Poster Session: December 5, 2010 Time: 6:00pm 8:00pm
  • Mantle Cell Lymphoma Goy A. Meet-the-Experts Session: December 5, 2010 Time: 11:00 am


  • 3273: Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor in Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS) Goldberg S., et al. Poster Session: December 6, 2010 Time: 6:00pm 8:00pm
  • 3453: One-Year Post-Transplant Serum Ferritin Level Is a Predictor of Long-Term Survival Following Allogeneic Transplantation Goldberg S., Elmann M., Kaminetzky M., Sidhom E., Mato A., Shah J., Stanislaus G., Limor S., Weinstein A., Jones E., Granholm K., Marrero W., Szyperek K., Polanco A., Yaniga J., Hanrahan M., Amatucci T., Sutherland P., McKiernan P., Pecora A., Donato M., and Rowley S. Poster Session: December 6, 2010 Time: 6:00pm 8:00pm

Personalized Medicine and Hematologic Malignancies

  • Moving Towards Personalized Medicine in Hematologic Malignancies, Goy A. Symposia: Peabody Orlando Hotel, Plaza International Ballroom DEF at December 3, 2010 Time: 12:30 pm - 4:30 pm


Contact: Amy Leahing
John Theurer Cancer Center

Related medicine news :

1. John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients
2. John Theurer Cancer Center offers breakthrough radiation measurement technology
3. Leading physicians and researchers at the John Theurer Cancer Center present research at ASCO
4. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
5. The John Theurer Cancer Center recognizes medical physics team for safety track record
6. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
7. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
8. John Theurer Cancer Center to present innovative research at 2 surgical meetings
9. Enhancing arrest of cell growth to treat cancer in mice
10. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
11. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
Post Your Comments:
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also ... many people who find their cholesterol levels and weight are creeping up are more ... they don’t have any of the other symptoms. , Thyroid hormone plays a major ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
(Date:11/24/2015)... ... November 24, 2015 , ... The ... comes to several aspects of orthopedic care. They have received recognition for excellence ... general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion based ...
(Date:11/24/2015)... ... 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus Medical ... the United States grew 400 percent between 1999 and 2010, far more than the ... percent of all fatal drug overdoses. (1) , While oxycodone and the extended release ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... N.Y. , Nov. 24, 2015 Avery ... System, is pleased to announce the appointment of ... Dr. ... pediatric cardiology at Children,s Hospital, Uppsala University, Uppsala and ... From 1984-1986, he was a fellow at the Cardiovascular ...
(Date:11/24/2015)... , November 24, 2015 ... --> adds Latest Guidebook for ... of 217 pages published in November 2015 to ... online business intelligence library at . ... of the fastest growing global economies with a ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
Breaking Medicine Technology: